
Elahere gets UK approval in platinum-resistant ovarian cancer
Elahere (mirvetuximab soravtansine) has become the first folate receptor-alpha (FRα) targeted antibody-drug conjugate (ADC) licensed in the UK for the treatment of adults with platinum-resistant high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer. It is approved in patients who have received one to three prior systemic treatment… Read More















